Clinical Trials Browser

Phase 2 × OTHER × pembrolizumab × Clear all

NCT03632941 2026-06-04

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer

Phase 2 Terminated

8 enrolled 13 charts

Breast Neoplasms, Neoplasms

NCT04895735 2026-06-04

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Phase 2 Active not recruiting

45 enrolled 12 charts

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT04955743 2026-06-04

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Phase 2 Terminated

18 enrolled 13 charts

CNSDermatologicGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

NCT05239624 2026-06-04

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Phase 2 Recruiting

Carcinoma, Transitional Cell

NCT05741164 2026-06-04

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT07021989 2026-06-04

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Phase 2 Not yet recruiting

Hodgkin Disease

NCT04753879 2026-06-03

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04230109 2026-06-02

NeoSTAR

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT03835819 2026-06-01

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Phase 2 Active not recruiting

18 enrolled 17 charts

Endometrial Neoplasms

NCT04825990 2026-06-01

POINT

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT04858269 2026-06-01

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT05231122 2026-06-01

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03402880 2026-05-29

ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase 2 Withdrawn

Extensive Stage Small Cell Lung Carcinoma

NCT05203445 2026-05-29

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

Phase 2 Active not recruiting

6 enrolled 9 charts

Breast Neoplasms

NCT06123338 2026-05-28

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Phase 2 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT07610525 2026-05-28

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06812858 2026-05-22

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

Phase 2 Recruiting

Hodgkin Disease

NCT07601737 2026-05-22

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03430700 2026-05-20

PROMPT

Phase 2 Completed

20 enrolled 10 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05675579 2026-05-20

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Phase 2 Active not recruiting

Breast Neoplasms

NCT06863402 2026-05-20

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05761951 2026-05-19

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT02362997 2026-05-18

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Phase 2 Completed

82 enrolled 20 charts

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT04032418 2026-05-18

Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05034536 2026-05-18

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

Phase 2 Active not recruiting

Melanoma

NCT05355051 2026-05-18

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

Phase 2 Recruiting

Hodgkin Disease

NCT06083844 2026-05-18

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Phase 2 Recruiting

Ovarian Neoplasms

NCT07594015 2026-05-18

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

Phase 2 Recruiting

Endometrial Neoplasms

NCT04565496 2026-05-15

PEM-PRO

Phase 2 Withdrawn

Prostatic Neoplasms

NCT05221645 2026-05-15

P+R-ICE

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT02312557 2026-05-14

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Phase 2 Active not recruiting

58 enrolled 13 charts

Prostatic Neoplasms

NCT07089992 2026-05-14

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

Phase 2 Recruiting

Liposarcoma, Sarcoma, Perivascular Epithelioid Cell Neoplasms

NCT02841748 2026-05-13

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

Phase 2 Completed

100 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04369937 2026-05-13

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

18 enrolled 14 charts

Squamous Cell Carcinoma of Head and Neck

NCT07172256 2026-05-13

CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05420948 2026-05-12

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03179917 2026-05-11

Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

Phase 2 Active not recruiting

Hodgkin Disease

NCT04348747 2026-05-11

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Phase 2 Recruiting

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT04848337 2026-05-11

PLANE-PC

Phase 2 Active not recruiting

45 enrolled 8 charts

Neuroendocrine Tumors

NCT02296684 2026-05-08

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

67 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02399371 2026-05-08

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Phase 2 Completed

65 enrolled 12 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT04414540 2026-05-08

Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients

Phase 2 Active not recruiting

21 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck

NCT06898970 2026-05-08

Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

Phase 2 Active not recruiting

Hemangiosarcoma

NCT07087860 2026-05-08

RECIPE-B1

Phase 2 Recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT07484139 2026-05-08

NEO COMBAT XL

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06242834 2026-05-07

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Active not recruiting

Lymphoma, B-Cell

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03349450 2026-05-06

SPiReL

Phase 2 Completed

25 enrolled 18 charts

LymphoidSarcoma

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT06266338 2026-05-06

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT06845319 2026-05-06

NeoCARD

Phase 2 Recruiting

Triple Negative Breast Neoplasms